Table 2 The difference in characteristics by the presence of sirolimus use after surgical pleural covering of entire lung (total pleural covering and modified total pleural covering)

Age^a, year

37.0 (35.0–38.5)

39.5 (34.2–43.2)

Body mass index^a

20.4 (19.2–21.5)

18.9 (17.6–20.0)

Comorbidities^a

 TSC-LAM

0

1 (12.5)

 AML

6 (37.5)

4 (50)

Serum albumin^a, g/dL

4.3 (4.3–4.8)

4.0 (3.9–4.4)

Serum VEGF-D^a, pg/mL

910 (655–1182)

938 (907–3078)

%LAV^a, %

11.7 (3.6–20.9)

9.7 (6.4–12.0)

Pneumothorax episode^a, times

2 (1–2.7)

2 (1–2.2)

History of surgical procedure^a

6 (37.5)

2 (25)

History of pleurodesis^a

4 (25)

1 (12.5)

Oxygen therapy^b

3 (18.8)

1 (12.5)

Sirolimus induction before SPC

1 (6.2)

0

Bronchodilator treatment^a

2 (12.5)

1 (12.5)

Approach,

 VATS

13 (81.2)

7 (87.5)

 Thoracotomy

3 (18.8)

1 (12.5)

Postoperative complication

 PAL (≥ 5 days)

6 (37.5)

3 (37.5)